I. Epidemiological profile

Population: 2013
- High transmission (> 1 case per 1000 population): 461,000
- Low transmission (0–1 cases per 1000 population): 361,000
- Malaria-free (0 cases): 157,000
Total: 1,079,000

II. Intervention policies and strategies

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Policies/strategies</th>
<th>Yes/No</th>
<th>Year adopted</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITN</td>
<td>ITN/LLINs distributed free of charge</td>
<td>Yes</td>
<td>2007</td>
</tr>
<tr>
<td></td>
<td>ITN/LLINs distributed to all age groups</td>
<td>Yes</td>
<td>2007</td>
</tr>
<tr>
<td>IRS</td>
<td>IRS is recommended</td>
<td>Yes</td>
<td>1945</td>
</tr>
<tr>
<td></td>
<td>DDT is authorized for IRS</td>
<td>No</td>
<td>–</td>
</tr>
<tr>
<td>Larval control</td>
<td>Use of larval control recommended</td>
<td>No</td>
<td>–</td>
</tr>
<tr>
<td>IPT</td>
<td>IPT used to prevent malaria during pregnancy</td>
<td>N/A</td>
<td>–</td>
</tr>
</tbody>
</table>

III. Financing

Sources of financing:
- GoG
- Global Fund
- World Bank
- USAID/PMI
- WHO/UNICEF
- Others

IV. Coverage

ITN and IRS coverage:
- 100% at high risk protected with ITNs
- 100% at high risk protected with IRS

V. Impact

Confused malaria cases per 1000 and ABER

Brazil

Parasites and vectors
- Major plasmodium species: P. falciparum (18%), P. vivax (82%)

Programme phase
- Control
- Reported confirmed cases: 17,546
- Reported deaths: 41

Antimalaria treatment policy
- First-line treatment of unconfirmed malaria
  - AL + PQ (14d), AS + MQ + PQ (14d)
  - 2012
- Treatment failure of P. falciparum
  - CQ + PQ (14d)
- Treatment of P. vivax
  - CQ + PQ (14d)
  - 2006

Dosage of primaquine for radical treatment of P. vivax
- 0.5 mg/kg /2 days

Primaquine distributed vs reported P. vivax cases
- Yes
- No

Suspected cases tested
- Yes
- No

Reported deaths:
- Yes
- No

AL, CQ, PQ

AS, MQ, PQ

CQ, PQ

CQ + PQ

CQ + MQ

CQ + MQ + PQ

CQ + PQ (14d)

CQ + PQ (28d)

CQ + PQ (94d)

PF-RATIO

Type of RDT used
- PF - all species (Combo)

Therapeutic efficacy tests (clinical and parasitological failure, %)
- Uncomplicated
  - Median
  - 5.2

Management and other costs
- Antimalarial medicines
- Insecticides & spray materials
- Diagnostics
- Human resources & technical assistance
- Health facilities (basic care)
- Funding source(s): USAID/PMI

Funding includes <1% of total contributions

Notes:
- Infected & treated
- Diagnosed
- Antimalarial
- Monitoring & evaluation
- ABR

WORLD MALARIA REPORT 2014 | 79